‘Some way to go’ before decision on Biogen Alzheimer’s drug, says UnitedHealth

There is “some way to go” before UnitedHealth Group has the clarity to make a coverage decision on Biogen’s Alzheimer’s disease drug Aduhelm, according to the CEO of the healthcare company.